Immunotherapy: Immune-modified response criteria — an iterative learning process?

Immunotherapy: Immune-modified response criteria — an iterative learning process?Immunotherapy: Immune-modified response criteria — an iterative learning process?, Published online: 13 March 2018; doi:10.1038/nrclinonc.2018.36Patients with solid tumours can have unusual patterns of response to anticancer immunotherapy, necessitating the adaptation of traditional response criteria. A recent retrospective analysis of data from patients with four different types of solid tumours treated with the anti-programmed cell death 1 ligand 1 (PD-L1) antibody atezolizumab confirms the previous experience in patients with melanoma and provides several new insights.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research